Narrow search
Showing 1 - 10 of 23,256
Cover Image
Reference pricing and cost-sharing : theory and evidence on German off-patent drugs ; conference paper
Herr, Annika; Stühmeier, Torben; Wenzel, Tobias - 2014
-patent pharmaceuticals. We present a theoretical model with price-sensitive and loyal consumers that shows that a decrease in the reference …
Persistent link: https://www.econbiz.de/10010489291
Cover Image
Parallel imports and manufacturer rebates : evidence from Germany
Birg, Laura - 2019
pharmaceuticals on competition by parallel imports. First, I analyze the effect of a manufacturer rebate on competition by parallel …
Persistent link: https://www.econbiz.de/10011949028
Cover Image
Die Rolle des Staates in der Impfstoffproduktion : technologische Restriktionen und ökonomische Ableitungen
Kirchhoff, Jasmina - 2021
Die Bundesregierung und die Europäische Kommission mussten in den letzten Wochen viel Kritik bezüglich ihrer Impfstoffbeschaffungsstrategie zur Eindämmung der Corona-Pandemie einstecken. Vor dem Hintergrund zu schleppend erscheinender Impfstofflieferungen und der zunehmenden Gefahr durch die...
Persistent link: https://www.econbiz.de/10012434819
Cover Image
Arzneimittelversorgung und -produktion gefährdet : AMNOG-Reform auf dem Prüfstand
Kirchhoff, Jasmina - 2022
Erstattungsbetragsverhandlungen innovativer Arzneimittel werden als Gefahr für die zukünftige Versorgung der Patienten und für den Forschungs- und … zweckmäßigen Vergleichstherapie gleichwertige Arzneimittel schlechter gestellt werden. Zum anderen können nur noch … Arzneimittel beeinflusst darüber hinaus die Standortentscheidungen pharmazeutischer Unternehmen. …
Persistent link: https://www.econbiz.de/10013468282
Cover Image
Competitive pricing within pharmaceutical classes : evidence on ‘‘follow-on’’ drugs in Germany 1993 - 2008
Mueller, Michael T.; Frenzel, Alexander - In: The European journal of health economics : HEPAC ; … 16 (2015) 1, pp. 73-82
Persistent link: https://www.econbiz.de/10011300287
Cover Image
Pharmaceutical prices under regulation : tiered co-payments and reference pricing in Germany
Herr, Annika; Suppliet, Moritz - 2012
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to … (no. of firms) suggests a significant but small negative correlation with prices. -- pharmaceuticals ; prices ; co …
Persistent link: https://www.econbiz.de/10009522774
Cover Image
The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25
Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …
Persistent link: https://www.econbiz.de/10012291135
Cover Image
The impact of pricing and patent expiration on the demand for pharmaceuticals : an examination of the use of broad-spectrum antimicrobials
Kaier, Klaus - 2010
The aim of the analysis was to determine whether demand in Germany for antibiotics is driven by prices that drop considerably when generic substitutes become available. A time-series approach was therefore carried out to explore price elasticities of demand for two different classes of...
Persistent link: https://www.econbiz.de/10009127962
Cover Image
Authorized generic entry prior to patent expiry : reassessing incentives for independent generic entry
Appelt, Silvia - 2010
Patent holders frequently attempt to mitigate the loss of monopoly power by authorizing generic entry prior to patent expiry (early entry). Competition in off-patent pharmaceutical markets may be adversely affected if early entry substantially impairs the attractiveness of subsequent market...
Persistent link: https://www.econbiz.de/10003964934
Cover Image
Authorized generic entry prior to patent expiry : reassessing incentives for independent generic entry
Appelt, Silvia - 2010
Patent holders attempt to mitigate the loss of monopoly power by authorizing generic entry prior to patent expiry (early entry). Off-patent competition may be adversely affected if early entry substantially lowers the attractiveness of subsequent generic entry. This study assesses the impact of...
Persistent link: https://www.econbiz.de/10008939409